Susquehanna International Group’s Kymera Therapeutics KYMR Stock Holding History

Susquehanna International Group’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.67M	Sell	44,100 -10,800	-20%	-$855K	﹤0.01%	4836
2025 Q4	$4.27M	Buy	54,900 +16,600	+43%	+$1.12M	﹤0.01%	4272
2025 Q3	$2.17M	Buy	38,300 +23,400	+157%	+$1.06M	﹤0.01%	5600
2025 Q2	$650K	Buy	14,900 +7,400	+99%	+$255K	﹤0.01%	8554
2025 Q1	$205K	Buy	7,500 +1,900	+34%	+$69.3K	﹤0.01%	10880
2024 Q4	$225K	Sell	5,600 -11,800	-68%	-$533K	﹤0.01%	10458
2024 Q3	$824K	Buy	+17,400	New	+$768K	﹤0.01%	7277
2023 Q3	–	Sell	-16,500	Closed	-$379K	–	12520
2023 Q2	$379K	Sell	16,500 -2,300	-12%	-$65.9K	﹤0.01%	8956
2023 Q1	$557K	Buy	+18,800	New	+$606K	﹤0.01%	8300
2022 Q4	–	Sell	-10,500	Closed	-$229K	–	13099
2022 Q3	$229K	Buy	+10,500	New	+$277K	﹤0.01%	10493

Other funds holding KYMR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Susquehanna International Group's KYMR Position: Q1 2026 in Review

Susquehanna International Group increased its Kymera Therapeutics (KYMR) stake by 331% in Q1 2026, buying an estimated $1.54M and bringing the position to 25,403 shares worth $2.12M. The position accounts for ﹤0.01% of the portfolio, ranked #6053.

Susquehanna International Group first reported a position in KYMR in Q1 2021 and has held it in 20 quarters since. The position peaked at $2.51M in Q2 2025. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

Susquehanna International Group held 25,403 shares of Kymera Therapeutics worth $2.12M as of Q1 2026.
Susquehanna International Group bought 19,503 Kymera Therapeutics shares in Q1 2026, an estimated $1.54M.
Kymera Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #6053 holding.
Susquehanna International Group first reported a position in Kymera Therapeutics in Q1 2021 and has held it in 20 quarters since.
Susquehanna International Group's Kymera Therapeutics position peaked at $2.51M in Q2 2025.
256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.